



Black, Rachel; Lester, Susan Elizabeth; Dunstan, Emma Victoria; Shahram, Farhad; Nadji, Abdolhadi; 
Bayat, Noushin; Saeedfar, Kayvan; Ziaei, Naghmeh; Hill, Catherine Louise; Rischmueller, Maureen; 
Davatchi, Fereydoun  
Fc-gamma receptor 3B copy number variation is not a risk factor for Behçet’s disease, International 
Journal of Rheumatology, 2012; 2012:167096 
 
Copyright © 2012 Rachel Black et al.  
This is an open access article distributed under the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is 




























Open Access authors retain the copyrights of their papers, and all open access articles are 
distributed under the terms of the Creative Commons Attribution license, which permits 








26th  November 2012 
Hindawi Publishing Corporation
International Journal of Rheumatology
Volume 2012, Article ID 167096, 4 pages
doi:10.1155/2012/167096
Research Article
Fc-Gamma Receptor 3B Copy Number Variation
Is Not a Risk Factor for Behc¸et’s Disease
Rachel Black,1 Sue Lester,1 EmmaDunstan,1 Farhad Shahram,2 Abdolhadi Nadji,2
Noushin Bayat,2, 3 Kayvan Saeedfar,2, 4 Naghmeh Ziaei,2 Catherine Hill,1, 5
Maureen Rischmueller,1, 5 and Fereydoun Davatchi2
1 Department of Rheumatology, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South, SA,
5011, Australia
2 Rheumatology Research Centre, Tehran University of Medical Sciences, Shariati Hospital, Kargar Avenue,
Tehran 14114, Iran
3 Rheumatology Department, Baqyiatallah University of Medical Sciences, Baghiatallah hospital, Molla Sadra Street,
Tehran 14359, Iran
4 Chronic Respiratory Diseases Research Centre, Shahid Beheshti University of Medical Sciences, Massih Daneshvari Hospital,
Shaid Bahonar Street, Tehran 19556, Iran
5 Discipline of Medicine, The University of Adelaide, Adelaide, SA 5005, Australia
Correspondence should be addressed to Rachel Black, rachel.black@health.sa.gov.au
Received 13 February 2012; Accepted 10 April 2012
Academic Editor: Lorenzo Beretta
Copyright © 2012 Rachel Black et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Behc¸et’s disease (BD) is an immune-mediated systemic vasculitis associated with HLAB51. Other gene associations are likely and
may provide further insight into the pathogenesis of this disease. Fc-gamma receptors play an important role in regulating immune
function. Copy number variation (CNV) of the Fc-gamma receptor 3B (FCGR3B) gene is associated with other inflammatory
conditions and may also play a role in BD. The aim of this study was to determine whether CNV of the FCGR3B gene is associated
with BD or its clinical features. FCGR3B copy number was determined for 187 Iranian patients and 178 ethnicity-matched controls
using quantitative real-time PCR. The genotype frequencies were comparable in both BD patients and controls. The odds ratio for
low copy number (<2CN) was 0.6 (P = 0.16) and the odds ratio for high copy number (>2CN) was 0.75 (P = 0.50). There was
no association found between high or low CN of the FCGR3B gene and BD or its clinical features in this Iranian population. We
are the first to report this finding which, when looked at in the context of other genetic studies, gives us further insight into the
complex pathogenesis of BD.
1. Background
Behc¸et’s disease (BD) is an immune-mediated, systemic
vasculitis, in which blood vessels of all sizes (small, medium,
and large) in both the venous and arterial circulation can be
aﬀected. Clinically it is characterised by recurrent aphthous
ulcers of the mouth and/or genitals in combination with
other systemic manifestations involving the skin, eyes, joints,
vessels, gastrointestinal tract, or central nervous system [1].
The pathogenesis of BD is not understood. It lies at
the crossroad between autoimmune and autoinflammatory
disorders [2], may be triggered by infectious agents, and is
characterised by a number of immunological aberrations,
such as neutrophil hyperactivity (reviewed in [3, 4]). There
is also clearly a genetic component. BD is most frequently
observed in populations around the Mediterranean basin,
the Middle East, and the Far East, and the clustering of BD
in populations along the ancient Silk Route suggests that an
inherited tendency to BD was spread by travellers along these
trading routes. Multiple studies, in multiple populations,
have confirmed a strong association between HLA-B51 and
BD [4], but other genes are also likely to be involved. Copy
number variation in the FCGR3B gene is one candidate gene
of interest.
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Copy number variation (CNV) is departure from the
normal diploid number of genes (n = 2) which may
arise from gene duplication and deletion events and which
may contribute substantially to quantitative variation in
expression. An increasing number of CNVs have been
characterised in the human genome with implications for
both evolution and disease susceptibility [5]. CNV has been
well characterised in the FCGR gene cluster on chromosome
1q23. This cluster carries 5 highly homologous genes that
encode for low aﬃnity receptors for IgG-complexed antigens,
which are expressed widely throughout the haematopoietic
system. These low aﬃnity Fc-gamma receptors are involved
in the regulation of a multitude of innate and adaptive
immune responses, with implications for both response to
infection and susceptibility to autoimmunity [6].
CNV in the FCGR3B gene is of particular interest.
FCGR3B is expressed almost exclusively on neutrophils [6],
and there is a clear correlation between gene copy number
and FCGR3B cell surface expression, neutrophil adherence to
IgG-coated surfaces, and immune complex uptake [7]. Fur-
ther, multiple studies have identified low FCGR3B CN (i.e.,
<2 copies) as a risk factor for systemic autoimmune diseases,
such as systemic lupus erythematosus [8–10], rheumatoid
arthritis [11, 12], and primary Sjo¨gren’s syndrome [9, 10].
We therefore examined the association between FCGR3B
CNV and BD, in a cohort of Iranian patients.
2. Methods
2.1. Subjects. Ethics approval was obtained from the
Rheumatology Research Centre’s ethics committee of Tehran
University of Medical sciences. A written informed consent
was obtained from all participants. 187 Iranian BD patients
were recruited from the Behc¸et’s clinic at Shariati Hospital,
Tehran, from early 2005 until late 2006. 178 ethnically-
matched, unrelated healthy volunteers were also recruited
as normal controls between 2005 and 2007. All the BD
patients recruited for this study met the International
Study Group (ISG) criteria for BD [13]. Baseline data was
collected using a standardised questionnaire at the time of
blood sampling. Information was obtained regarding their
age, gender, ethnicity, clinical features, and family history.
Serotyping for HLA-B51 status was carried out in selected
general immunologic laboratories within Iran using routine
commercial kits. Samples were then transported to Australia
for further analysis.
2.2. FCGR3B Copy Number (CN) Genotyping. Genomic
FCGR3B CN was determined using a quantitative real-time
PCR method, as previously described [11]. Briefly, a duplex
Taqman copy number assay was performed, using FCGR3B
specific primers (Applied Biosystems, Hs04211858, FAM-
MGB dual labeled probe) and RNase P (Applied Biosystems,
product 4403326, VIC-TAMRA dual-labeled probe) as the
reference assay. The assay was performed according to the
manufacturer’s instructions and PCR reactions were run on
an Applied Biosystems 7300 Real-Time PCR machine. All
samples were tested in triplicate, and fluorescence signals
Table 1: Baseline characteristics of patients with Behc¸et’s Disease.
Characteristic N (187)
Age at diagnosis (yrs), mean (±SD) 32.7 (8.2)
Female, n (%) 89 (48%)
Duration of symptoms at diagnosis (yrs),
mean (±SD) 6.7 (6.1)
HLA testing
HLA B51 positive 41/80 (51%)
HLA B5 positive 89/175 (51%)
Other tests
Skin pathergy 101/107 (94%)
Symptoms
Mucous membrane symptoms 187 (100%)
Skin symptoms 116 (62%)
Ocular symptoms 112 (60%)
Neurological symptoms 15 (8%)
Joint symptoms 58 (31%)
Gastrointestinal symptoms 13 (7%)





Table 2: Distribution of FCGR3B copy number (CN) variants in
Behc¸et’s (BD, N = 187) patients and controls (N = 178). When
compared to 2 CN, there was no evidence that <2 CN or >2 CN
genotypes were diﬀerent in frequency between BD patients and
controls (P = 0.16, 0.50, resp.).
FCGR3B CN BD Controls
1 15 (8.0%) 22 (12.4%)
2 161 (86.1%) 143 (80.3%)
3 10 (5.3%) 12 (6.7%)
4 1 (0.5%) 1 (0.6%)
Total 187 178
were normalised to ROX. Copy number was determined
using Copy Caller software (v.1.0, Applied Biosystems, USA),
and results were accepted only when calling confidence was
>80%, and ΔCq standard deviation between replicates was
<0.20.
2.3. Statistical Analysis. Analysis of FCGR3B CN in BD
patients compared to controls, and with clinical manifes-
tations within BD patients, was performed using logistic
regression. Analysis was performed using Statistica v6 (Stat-
soft, Tulsa OK, USA).
3. Results
187 BD patients were included in the study (mean age 32.7±
8.2, 48% female). Baseline characteristics are summarised in
Table 1. Of those who were tested for HLA status, 51% (89
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Table 3: Codistribution of FCGR3B copy number variation with clinical features within Behc¸et’s patients.
FCGR3B CNV
N P1
Clinical Parameter <2 =2 >2
Onset age: median (interquartile range) 26 (21,36) 26 (21,31) 25 (22,30) 187 0.67
Gender
Male: count (%) 8 (8.2%) 87 (88.8%) 3 (3.1%) 98
0.26
Female: count (%) 7 (7.9%) 74 (83.1%) 8 (9.0%) 89
HLA-B5
Neg: count (%) 8 (9.3%) 71 (82.6%) 7 (8.1%) 86
0.71
Pos: count (%) 7 (7.9%) 78 (87.6%) 4 (4.5%) 89
ESR
Normal: count (%) 9 (10.8) 70 (84.3%) 4 (4.8%) 83
0.40
Elevated: count (%) 4 (4.4%) 80 (88.9%) 6 (6.7%) 90
Genital apthosis2
No: count (%) 7 (10.8%) 53 (81.5%) 5 (7.7%) 65
0.79
Yes: count (%) 8 (6.6%) 108 (88.5%) 6 (4.9%) 122
Pseudofolliculitis
No: count (%) 10 (10.0%) 86 (86.0%) 4 (4.0%) 100
0.13
Yes: count (%) 5 (5.8%) 75 (86.2%) 7 (8.1%) 87
Erythema nodosum
No: count (%) 13 (9.4%) 116 (83.5%) 10 (7.2%) 139
0.98
Yes: count (%) 2 (4.2%) 45 (93.8%) 1 (2.1%) 48
Arthritis
No: count (%) 13 (8.9%) 126 (86.3%) 7 (4.8%) 146
0.17
Yes: count (%) 2 (4.9%) 35 (85.4%) 4 (9.8%) 41
Uveitis
No: count (%) 9 (8.3%) 91 (84.3%) 8 (7.4%) 108
0.61
Yes: count (%) 6 (7.6%) 70 (88.6%) 3 (3.8%) 79
Retinal vasculitis
No: count (%) 9 (7.5%) 104 (86.7%) 7 (5.8%) 120
0.81
Yes: count (%) 6 (9.0%) 57 (85.1%) 4 (6.0%) 67
Venous thrombosis
No: count (%) 15 (8.6%) 149 (85.6%) 10 (5.8%) 174
0.33
Yes: count (%) 0 (0%) 12 (92.3%) 1 (7.7%) 13
1
Ordinal P value (proportional odds ratio).
2All patients had oral apthosis.
of 175) were HLA B5 positive and 51% (41 of 80) were HLA
B51 positive.
The frequency of FCGR3B CN variants in both BD
patients and controls is presented in Table 2. Copy numbers
ranged from 1 to 4, and no null genotypes were observed in
this cohort. The genotype frequencies were comparable in
both BD patients and controls. The odds ratio for low copy
number (<2 CN) was 0.6 (95% CI 0.30, 1.21, P = 0.16) and
the odds ratio for high copy number (>2 CN) was 0.75 (96%
CI 0.33, 1.73, P = 0.50). Therefore there was no evidence that
either low or high FCGR3B was associated with BD, and in
fact, both low CN and high CN were slightly decreased in BD
patients relative to controls. Further, there was no evidence
of associations between FCGR3B CN variants and clinical
manifestations within BD patients as shown in Table 3.
4. Discussion
This is the first study to examine the relationship between
FCGR3B CN variants and Behc¸et’s disease, and we report
no evidence of an association in terms of either disease
susceptibility or clinical manifestations in this cohort of
patients from Iran. However, a previous study of Turkish
BD patients has reported associations between FCGR2A,
FCGR3A, and FCGR3B SNPs and BD, in terms of both
disease susceptibility and clinical manifestations [14], but
this remains unconfirmed.
Other studies have reported intriguing but conflicting
relationships between FCGR3B CN and vasculitis in the
context of diﬀerent diseases. For example, FCGR3B low CN
(<2) is associated with Granulomatosis with Polyangiitis
(Wegener’s Granulomatosis) and Microscopic Polyangiitis
(antineutrophil cytoplasmic antibody-associated systemic
vasculitidies) in one study [8], and high FCGR3B CN (>2)
in another [7], and no association has been observed with
vasculitis in conjunction with systemic lupus erythematosus
[15]. Further, similar to BD, susceptibility to other systemic
vasculitidies including Giant Cell Arteritis and Kawasaki’s
disease has also been linked to SNPs within the FCGR gene
cluster [16, 17].
The FCGR gene cluster is a complex genomic region,
with both SNP and CNV polymorphism. While we were
unable to demonstrate an association between FCGR3B
CN and BD in this study, there are undoubted links to
polymorphism in this region with vasculitic conditions. In
future, the challenge will be to integrate CNV and SNP
data into haplotypes in order to systematically evaluate
and contrast associations with diﬀerent vasculitidies. Such
studies will provide valuable insight into the underlying
pathogenetic mechanisms involved.
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